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Research Article
Adiponectin improves coronary no-reﬂow injury by
protecting the endothelium in rats with type 2
diabetes mellitus
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To determine the effect of adiponectin (APN) on the coronary no-reflow (NR) injury in
rats with Type 2 diabetes mellitus (T2DM), 80 male Sprague–Dawley rats were fed with
a high-sugar–high-fat diet to build a T2DM model. Rats received vehicle or APN in
the last week and then were subjected to myocardial ischemia reperfusion (MI/R) in-
jury. Endothelium-dependent vasorelaxation of the thoracic aorta was significantly de-
creased and serum levels of endothelin-1 (ET-1), intercellular cell adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were noticably increased in
T2DM rats compared with rats without T2DM. Serum APN was positively correlated with
the endothelium-dependent vasorelaxation, but negatively correlated with the serum level of
ET-1. Treatment with APN improved T2DM-induced endothelium-dependent vasorelaxation,
recovered cardiac function, and decreased both NR size and the levels of ET-1, ICAM-1
and VCAM-1. Hypoadiponectinemia was associated with the aggravation of coronary NR in
T2DM rats. APN could alleviate coronary NR injury in T2DM rats by protecting the endothe-
lium and improving microcirculation.
Introduction
Acute coronary syndromes (ACS), especially acute myocardial infarction (AMI), are very dangerous
and have a high mortality. Previously, continuous and effective myocardial reperfusion therapy was
proven to reduce significantly the myocardial infarction size, decrease the mortality and improve the
prognosis of patients. In clinical practice, percutaneous coronary intervention (PCI) has become the
most important method for cardiac revascularization [1]. However, approximately 10–30% of patients
with AMI experience coronary no-reflow (NR), after epicardial coronary stenosis or occlusion is re-
lieved by vascular recanalization with PCI. Coronary NR [2], may lead to severe hemodynamic dis-
orders, cause poor left ventricular remodeling and early post-infarction heart failure, and affect the
prognosis of patients, or even increase mortality during hospitalization [3]. A variety of treatment
strategies have been used to prevent or treat the phenomenon of NR, however, a complete and ef-
fective strategy has not yet been established, since different patients may have different pathogene-
ses. Therefore, it is important to investigate the mechanism of NR, so as to improve the therapeu-
tic effectiveness for ACS patients, and reduce and avoid the adverse cardiac events caused by NR.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of ACS than the normal population. More-
over, they usually have a larger infarction size and more severe damage than non-diabetes mellitus (DM) patients,
which might lead to a poor therapeutic effects after reperfusion, and increase significantly the risk of coronary NR
and mortality [4]. Therefore, it is of great importance to prevent increased NR risk in patients with T2DM so as to
improve cardiac function and decrease mortality.
Adiponectin (APN) is a fatty cytokine secreted by adipocytes, which is currently regarded as having three kinds of
biological effect: (1) insulin sensitizing (insulin metabolism adjusting), (2) anti-inflammatory (vascular protective)
and (3) anti-ischemic injury (cardioprotective). Interestingly, the plasma level of APN is correlated negatively with
the risk of ACS. A large number of epidemiological studies have found that most of patients with T2DM have hy-
poadiponectinemia [5]. Moreover, the risk of cardiovascular diseases will increase correspondingly with the decrease
in APN levels in patients with DM or adiposis [6]. At present, it is generally believed that systemic APN dysfunc-
tion causes the progression of coronary heart diseases and affects the outcome of these diseases in patients with
T2DM. Furthermore, giving exogenous APN alleviates myocardial ischemia/reperfusion (MI/R) injury significantly
[7]. Therefore, whether decreased APN levels could aggravate NR damage following MI/R in T2DM patients is worth
further investigation.
In this study, based on an adiposis-induced T2DM pathological model simulated by continuously feeding a
high-sugar–high-fat diet, an NRmodel was established by MI/R operation to observe whether low APN levels are re-
lated to the aggravation of coronary NR in T2DM. In addition, the potential for APN to alleviate coronary NR injury
by protecting vascular endothelium and improving myocardial microcirculation disorders was also investigated by
supplementing exogenous globular domain of APN (gAd).
Materials and Methods
Animals and dietary protocol
This study was performed in accordance with theGuiding Principles in theUse and Care of Animals, published by the
National Institutes of Health (NIH Publication No. 85—23, Revised 1996) and approved by the Institutional Animal
Care and Use Committee of Capital Medical University.
Eighty healthymale Sprague–Dawley (SD) rats weighing 110.0+−10.0g were divided randomly into two groups. The
control group (n=24) was given a normal diet. The high-sugar–high-fat diet group (n=56)was given adiet containing
20% sucrose, 10% triglyceride, 2.5% cholesterol and 0.5% sodium cholate (Huafukang Bioscience Company, Beijing,
China) for 32 weeks. Blood was drawn from the tail of each rat. Body weight, fasting blood glucose, fasting serum
insulin, the homeostasis model assessment of insulin resistance (HOMA-IR) and serum APN levels were monitored
regularly. Starting at 8 weeks into the 32-week diet, intraperitoneal injections of glucose tolerance test (IPGTT) were
performed every 4 weeks. An abnormal IPGTT was selected as the indicator of a successful model of T2DM. The
T2DM rats were randomly assigned to receive either vehicle (0.9% sodium chloride injection, 0.5 ml/day, tail vein
injection, n=11) or gAd (20 μg/kg/day, tail vein injection, n=12) (Biovision, USA) for the final week.
Fasting blood glucose test
After an 8 h fast, the glucose levels in the blood from the tail veins were measured using a glucose meter (OneTouch
SureStep Blood Glucose Meter, Johnson & Johnson Medical ltd., USA). Fasting blood glucose (FBG) was monitored
every 4 weeks.
Fasting serum insulin test
After an 8 h fast, the serum insulin levels in the blood from the tail veinsweremeasuredwith an [125I]Insulin Radioim-
munoassay Kit (BeijingNorthern BiologicalTechnology Research Institute,China). Fasting serum insulin (FINS)was
monitored every 4 weeks.
HOMA-IR analysis
The HOMA-IR was calculated according to the following formula:
HOMA-IR = FBG × FINS
22.5
where FBG and FINS are measured in mmol/l and IU/ml respectively.
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IPGTT examination
After an 8 h fast, a 2 g/kg 50% glucose solution was injected intraperitoneally, and then the glucose levels in the blood
from the tail veins were measured at 0, 30, 60 and 120 min using a glucose meter. Starting at week 8, IPGTT was
examined every 4 weeks.
Animal experimental protocol
At the end of the 32 weeks experimental period, rats were anesthetized with 10% chloral hydrate solution
(0.3ml/100 g). Myocardial ischemia was developed by exteriorizing the heart via a left thoracic incision and oc-
cluding the left anterior descending (LAD) coronary artery with a 6-0 silk slipknot. After 90 min of ischemia, the
slipknot was released and the myocardium was reperfused for 12 h. The sham-operated control rats underwent the
same surgical procedures except that the LAD was not occluded.
Rats were assigned randomly to one of four groups: (1) Sham + normal diet group: LAD without occlusion, total
time course 13.5 h; (2) MI/R + normal diet group: LAD with reversible occlusion, 90 min ischemia followed by
12-h reperfusion; (3) MI/R + Vehicle + T2DM group: LAD with reversible occlusion, 90 min ischemia followed by
12-h reperfusion; (4) MI/R + gAd + T2DM group: LAD with reversible occlusion, 90 min ischemia followed by 12-h
reperfusion.
Fasting serum APN assay
After an 8 h fast, the serum APN levels in the blood from the tail veins were measured with Rat Total
Adiponectin/Acrp30 Quantikine ELISA Kit (R&D Systems, Inc., USA) in accordance with the manufacturers’ in-
structions. Fasting serum APN was monitored every 2 weeks.
Determination of myocardial function
At the end of the 12-h reperfusion period, left ventricular (LV) function was continuously monitored via catheter
pressure transducer inserted into the LV via left carotid artery [8]. Left ventricular end diastolic pressure (LVEDP),
left ventricular systolic pressure (LVSP), and maximal rate of rise/decrease of left ventricular pressure (+− dp/dtmax)
were derived by BL-410 biological signal recording and analysis system.
Determination of NR size
The rats’ coronary NR ranges and ischemia areas were observed by Thioflavin-S (Sigma-Aldrich, USA), Evan’s blue
(Sigma-Aldrich, USA) and fluorescent microsphere (1–10 μm Molecular probes, Thermo Fisher Scientific Inc.,
USA) staining as in previous studies [9,10]. At the end of the 12-h reperfusion period, 1 ml/kg of a 4% solution
of Thioflavin-S [9] was injected into the heart to define the region of NR. Thioflavin-S shows bright blue–green flu-
orescence in 420-nm UV light, staining the endothelium, serving as a marker of perfusion. After MI/R, Thioflavin-S
was unable to flow into NR area due to microvascular obstruction, therefore, Thioflavin-S was used to observe zones
of NR. After 1 min, 1 ml/kg of a 2% solution of red fluorescentmicrosphere [10] was injected into the heart to observe
the NR. Red fluorescent microspheres show bright pink fluorescence in 420 nm ultraviolet (UV) light. The diameter
of fluorescent microsphere was similar to erythrocyte, the fluorescent microsphere was unable to enter NR area due
to microvascular obstruction. Therefore, the distribution of red fluorescence reflects cardiac perfusion in ischemia
part. After 1 min, LAD was re-ligated, 2 ml of 2% Evan’s blue was injected into the heart via the left auricle, then the
rat was killed and the heart obtained. The left and right auricle, right ventricle and remaining vessels were cut off,
residual blood was washed in ice heparin saline. The heart was sliced transversely into 6–8 pieces and photographed.
The slices were photographed under 420 nm UV light to identify the area of NR (ANR) and under standard light-
ing to identify the area at risk (AAR). The ANR shows no fluorescence, the area of reflow shows fluorescence, the
non-ischemia area stains blue, and AAR does not stain blue. The area described above was measured with Image-Pro
Plus 6.0 software (Media Cybernetics, Inc., USA), AAR/LV calculates ligation area, ANR/AAR reflects coronary NR
range. The higher ratio represents more severe injury.
Serum ET-1, ICAM-1 and VCAM-1 assay
Blood from the rats was collected at the end of 32 weeks and reperfusion for ET-1, ICAM-1 and VCAM-1 quantita-
tion was carried out to confirm endothelium injury and microcirculation disturbance. The serumwas analyzed spec-
trophotometrically (SoftMax Pro Software; Molecular Devices, Sunnyvale, USA) for ET-1, ICAM-1 and VCAM-1
concentration with rat ET-1, ICAM-1 and VCAM-1 ELISA kits (Wuhan ColorfulGene Biological Technology Co.,
LTD, China) in accordance with the manufacturer’s instructions [11].
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Thoracic aorta preparations and measurement of thoracic aorta
vasorelaxation
When the rats were anesthetized, thoracic aortas were removed quickly and placed in ice-cold Hepes-bufferred,
glucose-supplemented isotonic salt solution (mmol/l:NaCl 144.0, KCl 5.8,MgCl2 · 6H2O 1.2,CaCl2 2.5, glucose 11.0,
Hepes 5.0, pH 7.4). The surrounding tissue was cleaned and the aortas were cut into rings of 2 mm in length, and
thoracic aorta rings were attached to two wires (200 μm) connected to an isometric force transducer ((DMT610M,
Danish Myo Technology). The rings were suspended in organ bath chambers containing oxygenated (95% O2, 5%
CO2) Hepes buffer and maintained at 37◦C. The artery rings were stretched step by step to an optimal resting ten-
sion of 100 mmHg, which was maintained throughout the experiment. The rings were equilibrated for 2 h before
vasorelaxation measurements were taken, and the Hepes was replaced every 20 min. After the equilibration period,
the artery segments were exposed to Hepes buffer containing 60 mM potassium (mM: NaCl 89.8, KCl 60, MgCl2 ·
6H2O 1.2, CaCl2 2.5, Glucose 11.0, Hepes 5, pH 7.40) until reproducible contractile responses were obtained. Af-
ter washing with Hepes buffer, rings of thoracic aorta were precontracted with norepinephrine (10–5 mol/l). Once
a stable contraction was achieved, increasing concentrations of vasodilators (10–9–10–5 mol/L) were added to the
chamber to obtain cumulative concentration–response curves. Endothelium-dependent dilation was measured with
acetylcholine (ACh), and endothelium-independent dilation was measured with sodium nitroprusside (SNP).
Detection of APN protein by Western blot
After Thioflavin-S, Evan’s blue and fluorescent microsphere staining, the heart was quickly excised. The myocardium
from right ventricle, the NR area and reflow area of the ischemia area in the same rat was harvested for APN protein
detection using Western blot. Briefly, the tissue proteins were separated by SDS–PAGE and transferred to nitrocellu-
losemembranes. After being blockedwith 3% bovine serum albumin, the immunoblots were probedwith the primary
antibody (anti-APN and anti-β-actin) overnight at 4◦C. The membranes were incubated with goat anti-rabbit IgG
H&L (HRP) (1:3,000, Abcam, UK) at room temperature for 1 h and the blot was developed with a Supersignal chemi-
luminescence detection kit (Pierce, USA). The primary antibodies used were: rabbit anti-rat polyclonal APN (1:500,
Abcam, UK) and rabbit anti-rat polyclonal β-actin (1:2,000, Abcam, UK). The immunoblotting was visualized with
a Kodak Image Station 400 (Kodak, USA) and the blot densities were analyzed with Kodak 1D software. Results were
expressed as fold change over the control group (right ventricle).
Statistical analysis
Data were analyzed with SPSS 19.0 software (IBM, US). Results are presented as means+−SEM of n independent
experiments. Analysis of variance (ANOVA) and post hoc analysis were used for comparing means of more than
two samples, and Student’s t-test was used to compare two independent sample means. The correlation analysis was
carried out using linear correlation analysis. Values of P  0.05 were considered statistically significant.
Results
Establishment of T2DM rat model
In this study, T2DM rat model was established using long-term feeding (32 weeks) with a high-sugar–high-fat diet.
Rats fed with the high-sugar–high-fat diet showed listlessness, tiredness, fat body and slow response, while rats fed
with normal diet showed full spirit, normal eating and drinking, normal urine color and volume, and free and flexible
movement.
Compared with the normal rats of the same batch, high-sugar–high-fat rats got a rapidly body weight increase at
week 4 (Figure 1A) followed by further continuous and significant increases after that. These rats also had a significant
increased fasting blood glucose atweek 8 (Figure 1B) followed by continuous increasewith the prolongation of feeding
with high-sugar–high-fat diet.
There was no significant difference of fasting serum insulin level at week 4 was between normal rats and
high-sugar–high-fat rats. However, it increased significantly at week 8 (Figure 1C), and decreased significantly at
week 16 (Figure 1C), which suggests that insulin resistance phenomenon occurred at week 8 but insulin deficiency
at week 16 in the high-sugar–high-fat diet group.
The HOMA-IR index showed an increased trend in high-sugar–high-fat rats since week 4 and reached the peak
value at week 8 (Figure 1D), then gradually dropped, but still significantly higher than that of normal group at week
12. It decreased significantly and was close to the variation trend of fasting insulin at week 16, suggesting a good
connection between fasting insulin and HOMA-IR during the establishment of T2DM rat model.
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Figure 1. Establishment of type 2 diabetic rat modelwas induced by continuous high-sugar–high-fat feeding.
(A) Body weight, (B) fasting plasma glucose (FPG), (C) fasting plasma insulin, (D) HOMA-IR and (E) intraperitoneal injections of glucose
tolerance test (IPGTT) in high-fat–high-glucose diet-induced T2DM model in rats. **P<0.01 vs. normal diet group, n=23 rats/group.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Serum APN level in T2DM rats.
(A) Dynamic change of APN in high-fat–high-glucose diet-induced T2DM model in rats (n=23 rats/group). (B) APN level in different groups
at the end of 32 weeks (n=11–12 rats/group). *P<0.05, **P<0.01 vs. normal diet group; ##P<0.01 vs. T2DM group.
After week 8, the rats on the high-sugar–high-fat diet with a HOMA-IR index significantly higher than that of
normal rats of the same batch were selected for IPGTT, once every 4 weeks.
The rats showing a positive result (glucose 10 mmol/l 120 min after intraperitoneal injection of glucose, Figure
1E) were labeled asT2DM-positive rats and enrolled into T2DM group. The other rats not meeting the criterion were
removed from model group. A total of 23 rats of high-sugar–high-fat diet group were successfully established to the
T2DM model at the end of 32 weeks.
Serum APN level decreases in T2DM rats and is positively correlated with
the endothelium-dependent dilation of thoracic aortas
During the establishment of T2DM ratmodels, comparedwith the normal rats of the same batch, high-sugar–high-fat
rats displayed significantly increased APN levels at week 6. Then it decreased, but was still higher than that of normal
rats at week 8. Atweek 12, it gradually decreased, untilweek 16, when it was significantly lower than that of normal rats
(Figure 2A). The low serum APN level lasted until the end of 32 weeks when models were successfully established. It
suggested that serumAPN level tended to increase following the decrease of insulin and developed an APN resistance
phenomenon with a slightly earlier occurrence than insulin at weeks 6–8 during the establishment of T2DM rat
models. At the end of 32 weeks, the serumAPN level of type 2 diabetic rats was significantly lower than that of that of
normal rats (Figure 2B). However, the serumAPN level of T2DM rat models significantly rose back after intervention
of gAd at the end of 31 weeks (Figure 2B).
The thoracic aortas of T2DM rat models were collected at the end of 32 weeks. The endothelium-dependent and
-independent diastolic functions were detected with acetylcholine (ACh) and sodium nitroprusside (SNP), respec-
tively. As the results showed, ACh-induced endothelium-dependent diastolic function of the thoracic aorta had a
maximum diastolic value of 70% in T2DM rats, which was significantly lower than that in normal rats (with a maxi-
mum diastolic value of 93%), but it was significantly improvedwith amaximumdiastolic value of 81% after incubating
the thoracic aorta rings of T2DM rats with gAd (2 μg/ml) for 4 h (Figure 3A). However, there was no significant dif-
ference of SNP-induced endothelium-independent diastolic function between the two groups (Figure 3B). All these
result suggest that long-term stimulation of high-sugar–high-fat induced vascular endothelial dysfunction, and the
appropriately increasing APN level alleviated the endothelium dependent diastolic dysfunction.
Meanwhile, the serum endothelin-1 (ET-1) level was increased significantly in T2DM rat models compared with
that in normal (Figure 4A), suggesting that long-term toxicity of high sugar–high fat had caused damage to the en-
dothelium of DM rats, which may be one of the important reasons for the dysfunction of vascular endothelium. A
trend of damage alleviation appeared after administration of exogenous gAd (Figure 4A). In addition, serum ICAM-1
(Figure 4B) and VCAM-1 (Figure 4C) contents were significantly increased in T2DM rat models, suggesting that the
myocardial microcirculation system of T2DM rats might be damaged. Serum ICAM-1 content was slightly decreased
after administration of exogenous gAd.
In order to further confirm the relationship between the change of serum APN level and vascular endothelial
dysfunction and damage in T2DM rats, a correlation analysis was performed. It was found that serum APN level
6 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Endothelium-dependent vasorelaxation function in thoracic aorta.
(A) ACh-induced endothelium-dependent vasorelaxation of thoracic aorta in three experimental groups (n=5 rats/group). (B) SNP-induced
endothelium-independent vasorelaxation remained constant in three experimental groups (n=5 rats/group). *P<0.05, **P<0.01 vs. normal
diet control group; #P <0.05, ##P<0.01 vs. T2DM group.
Figure 4. Serum ET-1, ICAM-1 and VCAM-1 were increased in type-2 diabetic rats, and gAd treatment reversed
high-sugar–high-fat diet-related upregulation of serum ET-1 and ICAM-1.
(A) Serum ET-1, (B) ICAM-1 and (C) VCAM-1 in T2DM rats at the end of 32 weeks. *P< 0.05, **P< 0.01 vs. normal diet group; ##P<0.01 vs.
T2DM group. n=11–12 rats/group.
Figure 5. Correlation analysis of serum APN level with endothelium-dependent vasorelaxation function of thoracic aorta
and serum ET-1 level.
(A) Positive correlation between serum APN level and endothelium-dependent vasorelaxation function of thoracic aorta in T2DM rats at
the end of 32 weeks (n=10). (B) Negative correlation between serum APN level and serum ET-1 level in T2DM rats at the end of 32 weeks
(n=20).
at the end of 32 weeks was positively correlated with the endothelium-dependent diastolic function of the thoracic
aortic (Figure 5A), but negatively correlated with serum ET-1 (Figure 5B). It was confirmed that vascular endothelial
dysfunction and damage had a linear correlation with serum APN level in T2DM rats.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. NR injury in T2DM rats was increased after MI/R, and gAd treatment ameliorated the NR injury.
(A) LVSP, (B) +dp/dtmax, (C) AAR/LV and (D) NRA/AAR in different treatment groups subjected to MI/R. (C-a) and (D-a), representative
photographs of heart sections obtained from rats in sham, normal diet, DM with vehicle and gAd groups subjected to MI/R. (C-a) Dark
portion by Evan’s blue staining: non-ischemic, normal region; red portion: ischemic area (area at risk, AAR), negatively stained by blue dye.
(C-b) Myocardial ischemic area (AAR) in different groups. (D-a) Bright blue-green fluorescence portion by Thioflavin-S staining: reflow area;
bright pink fluorescence portion by fluorescent microsphere staining: reflow area; negatively stained by fluorescence: no reflow area. (D-b)
No reflow area expressed as percent of AAR. *P<0.05, **P<0.01 vs. sham groups; #P<0.05, ##P<0.01 vs. normal diet group; &P <0.05 vs.
T2DM group. n=6–7 rats/group.
Myocardial NR injury aggravates after MI/R and expression of APN
protein decreases in NR area of T2DM rats
The coronary NR rat model was established successfully by MI/R operation. LVSP (Figure 6A) and +dp/dtmax (Figure
6B) were clearly decreased after MI/R in T2DM rats compared with that in normal diet rats, which meant that my-
ocardial systolic dysfunction aggravated after MI/R in T2DM rat models.
After MI/R, the influence of surgical techniques on experimental results was excluded according to the ratio of
ischemia area to left ventricular area (there was no statistical difference in four groups, Figure 6C). NR area was
8 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 7. Serum ET-1, ICAM-1 and VCAM-1 were signiﬁcantly increased in the DM group after MI/R, and gAd treatment
improved endothelium injury and microcirculation disturbance.
(A) Serum ET-1, (B) ICAM-1 and (C) VCAM-1 in different treatments groups subjected toMI/R. **P<0.01 vs. sham groups; #P<0.05, ##P<0.01
vs. normal diet group; &P<0.05, &&P<0.01 vs. T2DM group. n=6–7 rats/group.
Figure 8. APN protein expression in the ischemia area of type 2 diabetic rats.
#P<0.05 vs. area of no reflow. n=6–7 rats/group. RV: right ventricular; NR: no reflow; R: reflow.
determinedbasedonThioflavin S, Evan’s blue fluorescentmicrosphere staining afterMI/R.The staining result showed
that NR area was increased significantly (Figure 6D) in T2DM rats compared with that in normal diet rats, suggesting
that the long-term stimulation with high-sugar–high-fat might cause more serious coronary NR after MI/R.
The level of serum ET-1, ICAM-1 and VCAM-1 were also increased significantly (Figure 7A-C) after the MI/R
surgery compared with normal diet rats, which suggested that vascular endothelial injury and the dysfunction of
myocardial microcirculation were aggravated further in T2DM rats after MI/R, which may be one of the reasons for
the aggravation of NR injury.
The expression of APN protein in the myocardial tissues of the right ventricle, NR and reflow areas in the same rat
were determined respectively, after Thioflavin S and Evan’s blue fluorescent microspheres staining. The expression
of myocardium APN was obviously lower in NR area than that in reflow zone (Figure 8), suggesting that APN level
might be the fundamental reason for the aggravation of NR injury in T2DM rats, and that endothelium injury and
myocardial microcirculation dysfunction might influence the biological functions of APN.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Coronary NR injury after MI/R was alleviated by supplementing
exogenous APN
LVSP (Figure 6A) and +dp/dtmax (Figure 6B) rose significantly after MI/R and the function of myocardial contraction
was dramatically improved in T2DM rats after supplementing gAd. Meanwhile, the area of myocardial NR signifi-
cantly shrank (Figure 6D) and the levels of serum ET-1, ICAM-1 and VCAM-1 were decreased significantly (Figure
7A-C).
Discussion
In this study, SD rats were fed with high-sugar and high-fat food for 32 weeks to build T2DM rat models and were
given with the intervention of exogenous gAd at the end of 31 weeks. The results of our study showed that serum
APN level in T2DM rat models was decreased at the end of 32 weeks and the variation trend of serum APN level
was close to that of serum insulin. An APN resistance phenomenon had an slightly earlier occurrence than that of
insulin. Endothelium-dependent diastolic function in the thoracic aorta of T2DM rat models was decreased, and the
levels of serum ET-1 level and adhesion molecules (ICAM-1 and VCAM-1) were increased. After intervention with
exogenous gAd, the function of endothelium-dependent vasodilatation was improved in some degree and the level of
serum ET-1 was decreased. Additionally, the level of serumAPN showed respectivel positive and negative correlation
with the maximum diastolic function of endothelium-dependent vasodilatation in the thoracic aorta and the level of
serum ET-1. The cardiac function of T2DM rat models was impaired significantly after ischemia/reperfusion. The
NR area was increased, while the expression level of myocardium APN protein in NR area was noticably decreased.
The level of serum ET-1 and adhesion molecules (ICAM-1 and VCAM-1) were distinctly increased. Meanwhile,
the cardiac function was notably improved, the NR area was decreased, and the level of serum ET-1 and adhesion
molecules (ICAM-1 and VCAM-1) were also reduced. The results of our study suggested that APN can reduce effec-
tively the injury of coronary NR after T2DM rat models suffered with MI/R, which may be realized by the protection
of endothelial tissue and improvement of microcirculation.
Cardiovascular disease is one of major complication in diabetes, accounting for more than 50% of the fatality
rate [12]. The morbidity and mortality of ischemic heart disease in diabetic patients are considerably higher than
the normal population. Myocardial ischemic areas of these patients are serious and the incidence of heart failure
is obviously increased with post-myocardial infarction [13]. The determination results of cardiac function and NR
area were consistent with related reports in this study, suggesting that the occurrence risk of coronary NR was raised
after T2DM was treated with reperfusion. It was reported that ischemic injury of endothelial cells was along with
microvascular obstruction, leukocyte and platelet effect, oxygen free radical mediated microvascular injury, vascular
dysfunction, tissue factor and coagulation effect, micro-embolization, mechanical nerve compression and so on, but
the underlying mechanisms of this phenomenon are not completely understood yet. Moreover, the patients with
NR may have individual differences, thus the mechanism of NR needs to be studied further in order to establish
personalized medicine, which is key to improving therapeutic efficacy.
Diabetic microangiopathy disease is found mainly in the retina, kidney, myocardium, nerve tissue and toe. In
this study, we focused on the influence of diabetic microangiopathy on macrovascular disease. In other words, the
dysfunction of myocardial microcirculation affected the coronary NR in T2DM after MI/R. Macrovascular and mi-
crovascular disease have common features with regard to endothelial dysfunction in T2DM [13], including damage
of vascular endothelial cells, dysfunction of endothelium-dependent vasodilation, disorder of hemodynamics, re-
duction of fibrinolytic ability, production of numerous growth factors, overexpression of adhesion molecules and
inflammatory cytokine, excess of ROS generatation, increase of oxidative stress and cell permeability [14-18].
In the progression of severe angina, AMI and MI/R injury, the synthesis and release of ET-1 are increased signifi-
cantly and the vascular affects ET-1 with hyperactivity. Additionally, the level of serum ET-1 in patients with ACS has
positive correlation with the occurrence and severity of coronary NR [19,20]. Previous research has shown that NR is
another manifestation of progressive myocardial damage and microcirculation injury after AMI was recovered with
reperfusion. The system of microcirculation injury is the main battlefield where NR occurs. ICAM-1 and VCAM-1
belong to the immunoglobulin of superfamily molecule, and regulate cell–cell and cell–extracellular matrix to con-
tract and combine with each other. Overexpression of ICAM-1 leads to increased endothelial cell permeability, which
facilitates leukocyte deformability enabling them to pass through endothelial cells and basement membrane to gather
and infiltrate in local tissue, further causing myocardial microvascular dysfunction and myocardial tissue damage
[21,22]. In the present study, the function of endothelium-dependent vasodilation in the aorta was observed in T2DM
rats. Meanwhile, the level of serum ET-1, ICAM-1 and VCAM-1 was further increased after ischemia/reperfusion.
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This further revealed that the occurrence of coronary NR was closely related with vascular endothelial injury and
myocardial microcirculation in T2DM with acute MI/R.
APN is primarily synthesized and secreted by fat cells, which is a highly negative correlation with varieties of
metabolic diseases, such as, obesity, hypertension, high cholesterol and T2DM [23]. A large number of clinical tri-
als have shown that populations with higher APN levels have a lower chance of diabetes and are lesslikely to suf-
fer from cardiovascular disease [24]. Animal experiments show that insulin resistance is improved noticably with
exogenous APN. The myocardial ischemic area of APN-knockout mice is larger than that of normal mice after is-
chemia/reperfusion. While the myocardial ischemic area reduces with the treatment of exogenous APN [25]. These
results imply that APN is not only related with the occurrence of diabetes, but also may be one of key factors that
influence on the occurrence of ischemic heart disease and prognosis. In this study, the decrease of serum APN was
correlated with the increase of the area of coronary NR after I/R and the decreased heart function in T2DM rats.
While NR was improved, perfusion was increased and heart function was improved after these rats were given ex-
ogenous APN, suggesting that the reduced expression level of APN may be one of factors leading to an increase of
NR in T2DM. In addition, we examined protein expression of APN in NR and recovery perfusion in ischemic heart
tissue in T2DM rats, and results revealed the APN protein expression in the former was less than that of the latter,
implying that microcirculation dysfunction may affect APN levels and further affect its biological function.
APN inhibitsmonocyte adhesion to endothelial cells by reducing the delivery of intracellularNF-κB (nuclear factor
κB) and the expression of adhesion molecules on vascular endothelial cells, resulting inan anti-atherosclerotic effect
[26]. Kusmic et al. [27] found that APN improvedmyocardial perfusion by increasing the signal of pLKB1 andAMPK
(AMP-activated protein kinase). Zhao et al. [28] demonstrated that APN improved skeletal muscle microcirculation.
Alvarez et al. [29] found that APN promoted the proliferation of human endothelial cells. APN also inhibited the out-
put of inflammatory cytokines and adhesionmolecules, including intercellular adhesionmolecule, vascular cell adhe-
sion molecules, E-selectin on endothelial cells [30]. Moreover, APN repaired vascular damage caused by angiotensin
II by mediating the activation of AMPK [31]. Our previous study also found that APN prevented endothelial injury
in various ways, such as C1q/TNF-related protein and APN receptors-1/AMPK/eNOS/nitric oxide signal pathways,
and further induced vasodilation [32]. In addition, APN inhibited oxidative stress and reduced the vascular damage
caused by itself through protein kinase A-dependent NF-κB signal pathways with I/R [33]. At the same time, it inhib-
ited vascular inflammation caused by tumor necrosis factor α (TNF-α) through caveolin-mediated neuraminidase
accumulation and activation [34]. These results suggested that high APN levels protected vascular endothelial cells,
and improved endothelium-dependent vasodilation and microcirculation. The results of this study showed that after
incubation of APN, endothelium-dependent vasorelaxation in the aorta was improved; serum ET-1 and the elevated
levels of ICAM-1 and VCAM-1 were obviously reduced after T2DM rats with MI/R, suggesting that APN played a
role in relieving coronary NR effect by protecting endothelial cells and improving the function of microcirculation.
In conclusion, our study confirmed that hypoadiponectinemiawas related to the aggravated degree of coronaryNR
in T2DM rats, andAPNprotects endothelial cells and improvesmyocardialmicrocirculation to alleviate the coronary
NR injury in T2DM rats. This results suggest that APN is related to ischemic heart disease that caused by multiple
risk factors, that is to say, APN in the treatment of cardiovascular disease may have broad applications in addition to
regulating glucose and lipidmetabolism disorders, which provide a new target and theoretical basis for the prevention
of coronary NR in clinical practice and decreasing MI/R injury.
Due to the limitation of diagnostic techniques, current basic experiments of NRmainly used large animals, for ex-
ample, pigs, dogs or rabbits.However, the application of these large animals to build a T2DMmodel suffers frommul-
tiple restrictions, such as costs and technology. Thus, our group built a T2DM model by feeding rats with long-term
high-sugar and -fat food. Based on this, the surgery of I/Rwas carried out, and the success of thismodelwas identified
by Thioflavin-S–Evan’s blue-fluorescent microsphere staining. However, we are still unable to apply a classical clinical
diagnosis of coronary NR via angiography due to the limitations of the rat body. In this study, Thioflavin-S–Evan’s
blue-fluorescent microsphere staining was just used for model identification. Nevertheless, two kinds of diagnostic
techniques, including delayed enhancement of MRI and radionuclide imaging, were actively explored in order to
further improve the establishment of coronary NR rat model.
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